Measuring Molecular Residual Disease in Colorectal Cancer After Primary Surgery and Resection of Metastases

Not Applicable

Active, not recruiting

• Conditions: Colorectal Cancer; Residual Disease
• Interventions: Diagnostic Test: blood draw

• Registration Number: NCT03189576
• Lead Sponsor: Tampere University Hospital

Brief Summary

Circulating tumour DNA (ctDNA) is a promising tool when monitoring the residual disease in colorectal cancer (CRC). Current staging procedures are insufficient to identify the patient cohort at high risk, who might benefit from additional adjuvant therapy.

We will show that the assessment of ctDNA is a non-invasive approach and easily taken at different time points via simple blood draw to monitor residual disease from the colorectal cancer patients after primary surgery. Minimal residual disease could be used in the future for individualized treatment decisions after primary surgery.

Detailed Description

Not available

Study Timeline

• Study Start: 2015-10-01
• Study First Submitted: 2017-06-14
• Study First Submitted QC: 2017-06-14
• Study First Posted: 2017-06-16
• Status Verified: 2023-05
• Last Update Submitted: 2023-05-25
• Last Update Posted: 2023-05-26
• Primary Completion: 2023-08-30
• Study Completion: 2023-08-30

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 37

Inclusion Criteria

• planned colorectal primary surgery

Exclusion Criteria

• unfit patients with dementia

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
CRC patients after primary surgery	blood draw	sequential blood draw taken to monitor residual disease

Primary Outcome Measures

Name	Time	Method
ctDNA level	3-6 months	residual disease measured by sequential blood draws

Trial Locations

Locations (1)

Tampere University Hospital; 🇫🇮 Tampere, Finland